Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Lymphoma, B-Cell 2Colorectal Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Platinum-resistant Ovarian Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Microsatellite Instability 1Melanoma 1Lung Neoplasms 1Liposarcoma, Myxoid 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 88Carboplatin 77Specimen Handling 76Magnetic Resonance Spectroscopy 63Pemetrexed 59Cisplatin 47durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32osimertinib 29Radiotherapy 29Radiosurgery 29Biopsy 26Blood Specimen Collection 25Gemcitabine 24Docetaxel 24Immunoglobulin G 23Disulfides 22Standard of Care 21Drug Therapy 21Etoposide 19Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × ALT-803 × 1 year × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡